Koers Medipharm Labs Corp Toronto S.E.
Aandelen
CA58504D1006
Farmaceutische producten
Omzet 2024 * | 43,06 mln. 31,3 mln. 29,31 mln. | Omzet 2025 * | 58,43 mln. 42,47 mln. 39,77 mln. | Marktkapitalisatie | 32,32 mln. 23,49 mln. 22 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -7 mln. -5,09 mln. -4,76 mln. | Nettowinst (verlies) 2025 * | -1 mln. -727K -681K | EV/omzet 2024 * | 0,75 x |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | 0,55 x |
K/w-verhouding 2024 * |
-5,33
x | K/w-verhouding 2025 * |
-
| Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,52% |
Recentste transcriptie over Medipharm Labs Corp
Managers | Titel | Leeftijd | Van |
---|---|---|---|
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Greg Hunter
DFI | Director of Finance/CFO | - | 08-02-21 |
Keith Strachan
PSD | President | - | 01-10-18 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Michael Bumby
BRD | Director/Board Member | 60 | 01-04-23 |
David Pidduck
CEO | Chief Executive Officer | - | 20-04-22 |
Shelley Martin
BRD | Director/Board Member | - | 22-06-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+39,33% | 6,01 mld. | |
-18,38% | 4,4 mld. | |
-9,17% | 3,17 mld. | |
+3,98% | 3,07 mld. | |
-3,41% | 2,51 mld. | |
+48,74% | 1,88 mld. | |
-4,82% | 1,73 mld. | |
-1,24% | 1,65 mld. | |
-8,96% | 1,58 mld. |